ArticleInternational journal of clinical and experimental medicine2015
Detection of pulmonary metastases with the novel radiolabeled molecular probe, (99m)Tc-RRL.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 4 citations in OpenAlex.
- Noninvasive PET Imaging of a Ga-68-Radiolabeled RRL-Derived Peptide in Hepatocarcinoma Murine Models.Molecular imaging and biology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo improve the detection of pulmonary metastases, experimental blood-borne pulmonary metastasis mouse models were established using three intravenously administered cell lines. In a previous study we demonstrated that (99m)Tc-radiolabeled arginine-arginine-leucine (RRL) could be used to non-invasively image malignant tumors.
methods(99m)Tc-RRL was prepared and injected intravenously in mice with pulmonary metastases that arose from the intravenous injection of HepG2, B16, and Hela cells. The bio-distribution and imaging of (99m)Tc-RRL were determined in different pulmonary metastases mouse models and in normal mice.
results(99m)Tc-RRL exhibited higher uptake values in the lungs of pulmonary metastatic mice compared to normal mice (P<0.05; 3.92±0.48% ID/g 2 h post-injection and 3.89±0.36% ID/g 4 h post-injection in metastatic hepatic carcinoma [HepG2]-bearing lungs; 5.49±0.84% ID/g 2 h post-injection and 5.11±0.75% ID/g 4 h post-injection in metastatic melanoma [B16]-bearing lungs; 3.72±0.52% ID/g 2 h post-injection and 3.51±0.35% ID/g 4 h post-injection in metastatic cervical carcinoma [Hela]-bearing lungs; 2.38±0.20% ID/g 2 h post-injection and 2.11±0.24% ID/g 4 h post-injection in normal lungs). The pulmonary metastatic lesions were clearly visualized using (99m)Tc-RRL.
conclusions(99m)Tc-RRL exhibited favorable metastatic tumor targeting and imaging properties, thus highlighting its potential as an effective imaging probe for detection of pulmonary metastases. (99m)Tc-RRL can be used as a reasonable supplement to (18)F-FDG imaging in the non-invasive imaging of tumor angiogenesis.
Indexed as
Identifiers
25932101PMC4402748W305397203What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.